Amarin Corp Plc (AMRN)

[zumantu]

HD, upon publication positive R-I results, the focus will be focused on clinical thought leaders in heart disease. It won't take much to move the flywheel towards administering Vascepa as an add-on

There are already labs that measure EPA levels (Boston heart)
And that testing will immediately increase.

The FDA is NOT a factor for R-I as it was with Anchor. Huge difference between approving a bio-marker versus factual outcomes study. In fact, as we've already seen I predict , insurance carriers will approve coverage ahead of FDA simply because the data will prove they're profits will skyrocket when insured diabetic CVD patients are on Vascepa